NASDAQ:BXRX Baudax Bio (BXRX) Stock Price, News & Analysis → Reclusive millionaire’s final warning about America (From Weiss Ratings) (Ad) Free BXRX Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$0.02▼$0.0250-Day Range$0.02▼$0.0352-Week Range$0.01▼$3.47Volume310,800 shsAverage Volume281,029 shsMarket Capitalization$1.14 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisEarningsHeadlinesInsider TradesOwnershipTrendsStock AnalysisEarningsHeadlinesInsider TradesOwnershipTrends Get Baudax Bio alerts: Email Address Ad Weiss RatingsReclusive millionaire’s final warning about AmericaThis crisis that's likly to begin in this country — before the election — could be bigger and more destructive than any crisis I've ever seen. That's why, no matter what you do, make sure you watch my short video and learn the three steps you need to take right now.Click here to learn how to prepare before it's too late. About Baudax Bio Stock (NASDAQ:BXRX)Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care related settings. The company offers ANJESO (meloxicam) injection for the management of moderate to severe pain, alone or in combination with other non-NSAID analgesics. It also develops BX1000, an intermediate-acting neuromuscular blocking agent (NMB) that is in phase II clinical trial; BX2000, an ultra- short acting NMB, which is in phase I clinical trial, as well as a proprietary blockade reversal agent; and BX3000, a NMB reversal agent that is in preclinical studies. Baudax Bio, Inc. was incorporated in 2019 and is based in Malvern, Pennsylvania.Read More Ad Weiss RatingsReclusive millionaire’s final warning about AmericaThis crisis that's likly to begin in this country — before the election — could be bigger and more destructive than any crisis I've ever seen. That's why, no matter what you do, make sure you watch my short video and learn the three steps you need to take right now.Click here to learn how to prepare before it's too late. BXRX Stock News HeadlinesOctober 18, 2023 | finance.yahoo.comBaudax Bio Announces Corporate UpdateOctober 2, 2023 | msn.comBaudax's (BXRX) Hemophilia A Drug Gets FDA's Orphan Drug TagJune 18, 2024 | Weiss Ratings (Ad)Reclusive millionaire’s final warning about AmericaThis crisis that's likly to begin in this country — before the election — could be bigger and more destructive than any crisis I've ever seen. That's why, no matter what you do, make sure you watch my short video and learn the three steps you need to take right now.September 28, 2023 | investorplace.comWhy Is Baudax Bio (BXRX) Stock Up 75% Today?September 28, 2023 | marketwatch.comBaudax Bio Shares Double After Orphan Drug Designation for TI-168September 28, 2023 | markets.businessinsider.comBaudax Bio: FDA Grants Orphan Drug Designation To TI-168 For Hemophilia A With InhibitorsSeptember 18, 2023 | finance.yahoo.comHere's Why Baudax Bio, Inc. (BXRX) Is a Great 'Buy the Bottom' Stock NowSeptember 7, 2023 | finance.yahoo.comBaudax Bio to Participate in the H.C. Wainwright Global Investment ConferenceJune 18, 2024 | Weiss Ratings (Ad)Reclusive millionaire’s final warning about AmericaThis crisis that's likly to begin in this country — before the election — could be bigger and more destructive than any crisis I've ever seen. That's why, no matter what you do, make sure you watch my short video and learn the three steps you need to take right now.August 23, 2023 | finance.yahoo.comBaudax Bio Announces Distribution of Series C Preferred Stock to Holders of its Common StockAugust 17, 2023 | finance.yahoo.comBaudax Bio Announces $1.9 Million Registered Direct Offering Priced At-The-Market under Nasdaq RulesAugust 16, 2023 | finance.yahoo.comBaudax Bio Reports Second Quarter 2023 Financial Results and Provides Business UpdateJune 30, 2023 | investorplace.comWhy Is Baudax Bio (BXRX) Stock Up 130% Today?June 8, 2023 | markets.businessinsider.comBaudax Bio (BXRX) Gets a Hold from Noble FinancialMay 22, 2023 | markets.businessinsider.comNoble Financial Sticks to Their Hold Rating for Baudax Bio (BXRX)May 15, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: MoonLake Immunotherapeutics (MLTX), Cocrystal Pharma (COCP) and Baudax Bio (BXRX)May 12, 2023 | finanznachrichten.deBaudax Bio, Inc.: Baudax Bio Reports First Quarter Financial Results and Provides Business UpdateMay 12, 2023 | baystreet.caBaudax Improves on Q1 ResultsMay 12, 2023 | msn.comRecap: Baudax Bio Q1 EarningsMay 12, 2023 | finance.yahoo.comBaudax Bio Reports First Quarter Financial Results and Provides Business UpdateMay 3, 2023 | finance.yahoo.comBaudax Bio to Present at the Sidoti Virtual Investor ConferenceMay 1, 2023 | finance.yahoo.comBaudax Bio Announces Closing of $4 Million Public OfferingApril 27, 2023 | msn.comWhy NETGEAR Shares Are Trading Lower By 18%? Here Are Other Stocks Moving In Thursday's Mid-Day SessionApril 27, 2023 | investorplace.comWhy Is Baudax Bio (BXRX) Stock Down 52% Today?April 27, 2023 | finance.yahoo.comBaudax Bio Announces Pricing of $4 Million Public OfferingApril 25, 2023 | msn.comBaudax Bio Soars after Positive Topline DataApril 25, 2023 | msn.comBaudax Bio's Nerve Blockade Aces Mid-Stage Study In Surgery PatientsSee More Headlines Receive BXRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Baudax Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/16/2023Today6/18/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:BXRX CUSIPN/A CIK1780097 Webwww.baudaxbio.com Phone484-395-2440Fax484-395-2471Employees9Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($9.23) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-58,790,000.00 Net MarginsN/A Pretax Margin-18,950.64% Return on EquityN/A Return on Assets-175.11% Debt Debt-to-Equity RatioN/A Current Ratio0.07 Quick Ratio0.07 Sales & Book Value Annual Sales$1.27 million Price / Sales0.90 Cash FlowN/A Price / Cash FlowN/A Book Value($14.93) per share Price / Book0.00Miscellaneous Outstanding Shares52,460,000Free Float52,408,000Market Cap$1.14 million OptionableNot Optionable Beta1.57 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesDr. Geraldine A. Henwood Ph.D. (Age 72)President, CEO & Director Comp: $633.25kMike ChoiVice President of Financial Planning & AnalysisMs. Natalie McAndrew (Age 53)Consultant & Principle Accounting Officer Dr. Chan Kim Yong Ph.D. (Age 50)Chief Scientific Officer & Director Key CompetitorsArtelo BiosciencesNASDAQ:ARTLGT BiopharmaNASDAQ:GTBPVirios TherapeuticsNASDAQ:VIRICingulateNASDAQ:CINGKazia TherapeuticsNASDAQ:KZIAView All Competitors BXRX Stock Analysis - Frequently Asked Questions How were Baudax Bio's earnings last quarter? Baudax Bio, Inc. (NASDAQ:BXRX) posted its quarterly earnings results on Wednesday, August, 16th. The company reported ($1.49) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($2.04) by $0.55. When did Baudax Bio's stock split? Baudax Bio's stock reverse split before market open on Wednesday, November 30th 2022. The 1-40 reverse split was announced on Wednesday, November 30th 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, November 30th 2022. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. What other stocks do shareholders of Baudax Bio own? Based on aggregate information from My MarketBeat watchlists, some companies that other Baudax Bio investors own include Sorrento Therapeutics (SRNE), Coty (COTY), NIO (NIO), VBI Vaccines (VBIV), ADMA Biologics (ADMA), Energy Transfer (ET), Remark (MARK), Designer Brands (DBI), Geron (GERN) and Matinas BioPharma (MTNB). This page (NASDAQ:BXRX) was last updated on 6/18/2024 by MarketBeat.com Staff From Our PartnersAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentia...Priority Gold | SponsoredBigger Than NVIDIA?With NVIDIA flying high, everyone is looking for the next breakout stock. But right now... There's only ...Behind the Markets | SponsoredBeta testers blew this thing upThis AI trading tool is probably unlike anything you've ever seen before… It scans the entire market and fi...Prosper Trading Academy | SponsoredRadical change coming — do this NOW to protect yourselfI recently uncovered a way the government could use the next crisis as a pretext to gain more control … and ra...Weiss Ratings | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Baudax Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Baudax Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.